Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Avindra Nath MD
Avindra Nath MD Associate Editor
Argye Hillis MD, MA
Argye Elizabeth Hillis MD, MA Associate Editor
Marinos Dalakas MD, FAAN
Marinos C. Dalakas MD, FAAN Advisory Board
See All Experts
story of the week
Published in Neurology

Journal Scan / Research · December 15, 2022

Safety and Efficacy of Continuous Subcutaneous Foslevodopa–Foscarbidopa in Patients With Advanced Parkinson's Disease

The Lancet Neurology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Werner Poewe MD

The Lancet Neurology
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
Lancet Neurol 2022 Dec 01;21(12)1099-1109, MJ Soileau, J Aldred, K Budur, N Fisseha, VS Fung, A Jeong, TE Kimber, K Klos, I Litvan, D O'Neill, WZ Robieson, MA Spindler, DG Standaert, S Talapala, EO Vaou, H Zheng, MF Facheris, RA Hauser

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated